

# COUNCIL OF EUROPE

## EUROPEAN COMMITTEE ON PHARMACEUTICALS AND PHARMACEUTICAL CARE (CD-P-PH)

(Partial Agreement)

### RESOLUTION AP-CPH (21) 2

*Adopted by the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH)  
(Partial Agreement)  
on 22 February 2021*

The European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH),

Considering that, under Article 1 of the Convention, the Parties have undertaken progressively to elaborate a Pharmacopoeia which shall be common to the countries concerned and which shall be entitled “European Pharmacopoeia”, and to take the necessary measures to ensure that the monographs constituting the European Pharmacopoeia shall become official standards applicable within their respective countries;

Having regard to Article 4, paragraph 3, of the Convention, which makes the Public Health Committee responsible for fixing the time-limits within which decisions of a technical character relating to the European Pharmacopoeia shall be implemented within the territories of the respective Parties;

Having regard to the decisions taken by the Committee of Ministers at its 1017th meeting, on 6 February 2008, pursuant to which the European Committee on pharmaceuticals and pharmaceutical care (CD-P-PH) would carry out the tasks of the Public Health Committee set out in the Convention on the Elaboration of a European Pharmacopoeia (ETS No. 50), as amended by the Protocol (ETS No. 134), and any reference to the “Public Health Committee” in the said Convention and Protocol should now be understood as referring to the European Committee on pharmaceuticals and pharmaceutical care (CD-P-PH);

Having regard to the adoption on 5 February 2021 by the European Pharmacopoeia Commission, in accordance with the provisions of Article 6, paragraph c of the Convention, of the revised version of the following monographs: *Candesartan cilexetil* (2573), *Irbesartan* (2465), *Losartan potassium* (2232), *Olmesartan medoxomil* (2600) et *Valsartan* (2423) the texts of which are set out in the appendix to this Resolution.

Having regard to the recommendation on 5 February 2021 by the European Pharmacopoeia Commission, in accordance with the provisions of Article 6, paragraph d of the Convention, which concerns the fixing of the date on which the revised version of the following monographs: *Candesartan cilexetil* (2573), *Irbesartan* (2465), *Losartan potassium* (2232), *Olmesartan medoxomil* (2600) et *Valsartan* (2423) shall be implemented within the territories of the parties,

Has decided to set 1 April 2021 the date on which the states parties to the Convention on the Elaboration of a European Pharmacopoeia shall implement, within their territories, the revised version of the following monographs: *Candesartan cilexetil* (2573), *Irbesartan* (2465), *Losartan potassium* (2232), *Olmesartan medoxomil* (2600) et *Valsartan* (2423).